<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40668802</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>7</Issue><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Impact of clonal hematopoiesis of indeterminate potential on arterial atherothrombosis and venous thromboembolism: Protocol for a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>e0328650</StartPage><MedlinePgn>e0328650</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0328650</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0328650</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Clonal hematopoiesis of indeterminate potential (CHIP) is a novel risk factor for thromboembolic events. While CHIP is linked to an increased risk of incident atherothrombosis (ATE), the link between these two conditions varies across studies. Furthermore, the association between CHIP and incident venous thromboembolism (VTE) has not yet been well characterized. Among patients with established ATE and VTE, it is still unclear how CHIP carriership influences their health outcomes. We aim to conduct a systematic review and meta-analysis to: i) determine the impact of CHIP carriership on incident ATE and VTE; and ii) evaluate the prevalence and clinical consequences of CHIP mutations among individuals with established ATE or VTE.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We will search MEDLINE, EMBASE, Scopus and CINAHL for randomized trials, cohort studies, or case control studies reporting thromboembolic events among adult CHIP carriers and non-carriers in two populations: i) individuals without prior ATE (coronary artery disease, myocardial infarction, ischemic stroke, peripheral arterial disease) or VTE (pulmonary embolism, deep vein thrombosis, superficial vein thrombosis); and ii) individuals with established ATE or VTE. Cross-sectional studies will be included to determine the prevalence of CHIP among individuals with established thromboembolic disease. The primary outcome will be incident ATE and VTE. Secondary outcomes will be: i) CHIP prevalence among individuals with established ATE or VTE; and ii) recurrent thromboembolism and treatment-associated bleeding among individuals with established ATE or VTE. We will use random-effects meta-analyses, with subgroup analyses by participant demographics, ATE and VTE risk factors, and CHIP-specific characteristics.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">By understanding the prognostic impact of CHIP carriership, our findings will inform future research on CHIP's role as a predictive biomarker for ATE and VTE in the general population and among individuals with established thromboembolic disease.</AbstractText><AbstractText Label="REGISTRATION" NlmCategory="BACKGROUND">This systematic review protocol was registered with the Internal Prospective Register of Systematic Reviews (PROSPERO, registration number CRD42024539923).</AbstractText><CopyrightInformation>Copyright: &#xa9; 2025 Todorovski et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Todorovski</LastName><ForeName>Angela</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0006-8530-5242</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Tzu-Fei</ForeName><Initials>TF</Initials><Identifier Source="ORCID">0000-0003-2407-9000</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sterling</LastName><ForeName>Evan</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-0599-6690</Identifier><AffiliationInfo><Affiliation>University of Ottawa Library, Ottawa, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Erin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrier</LastName><ForeName>Marc</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8296-2972</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siegal</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kekre</LastName><ForeName>Natasha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khalif&#xe9;</LastName><ForeName>Roy</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-7429-4724</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078202" MajorTopicYN="N">Systematic Reviews as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="N">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000082182" MajorTopicYN="Y">Clonal Hematopoiesis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050197" MajorTopicYN="Y">Atherosclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>I have read the journal's policy and authors of this manuscript have the following competing interests: M.C. reports research grants from Pfizer and consultancy honoraria from Pfizer, Bayer, Sanofi, Servier, and Leo Pharma. D.S. has received honoraria paid indirectly to her research institute from Astra Zeneca, BMS-Pfizer, Roche and Servier. R.K. reports consulting fees from CSL Behring and honoraria Bayer, CSL Behring, Novo Nordisk, Takeda, Pfizer, Roche and Sanofi. Other authors have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>16</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>16</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>16</Day><Hour>13</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40668802</ArticleId><ArticleId IdType="pmc">PMC12266447</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0328650</ArticleId><ArticleId IdType="pii">PONE-D-25-03488</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet. 2012;379(9828):1835&#x2013;46. doi: 10.1016/S0140-6736(11)61904-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(11)61904-1</ArticleId><ArticleId IdType="pubmed">22494827</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6717509</ArticleId><ArticleId IdType="pubmed">28636844</ArticleId></ArticleIdList></Reference><Reference><Citation>Soudet S, Jedraszak G, Evrard O, Marolleau JP, Garcon L, Pietri MAS. Is hematopoietic clonality of indetermined potential a risk factor for pulmonary embolism? TH Open. 2021;5(3):e338&#x2013;42. doi: 10.1055/s-0041-1733856</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1733856</ArticleId><ArticleId IdType="pmc">PMC8370792</ArticleId><ArticleId IdType="pubmed">34414354</ArticleId></ArticleIdList></Reference><Reference><Citation>Zon B, Sekar A, Clapham K, Niroula A, Bick AG, Gibson CJ, et al. Clonal Hematopoiesis and venous thromboembolism in the UK Biobank. Blood. 2023;142(Supplement 1):568&#x2013;568. doi: 10.1182/blood-2023-180764</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2023-180764</ArticleId></ArticleIdList></Reference><Reference><Citation>Marnell CS, Bick A, Natarajan P. Clonal hematopoiesis of indeterminate potential (CHIP): linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease. J Mol Cell Cardiol. 2021;161:98&#x2013;105. doi: 10.1016/j.yjmcc.2021.07.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2021.07.004</ArticleId><ArticleId IdType="pmc">PMC8629838</ArticleId><ArticleId IdType="pubmed">34298011</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler MD, Damask A, O&#x2019;Keeffe S, Banerjee N, Li D, Watanabe K, et al. Common and rare variant associations with clonal haematopoiesis phenotypes. Nature. 2022;612(7939):301&#x2013;9. doi: 10.1038/s41586-022-05448-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05448-9</ArticleId><ArticleId IdType="pmc">PMC9713173</ArticleId><ArticleId IdType="pubmed">36450978</ArticleId></ArticleIdList></Reference><Reference><Citation>Zon RL, Sekar A, Clapham K, Oren O, Niroula A, Bick AG, et al. JAK2-mutant clonal hematopoiesis is associated with venous thromboembolism. Blood. 2024;144(20):2149&#x2013;54. doi: 10.1182/blood.2024024187</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2024024187</ArticleId><ArticleId IdType="pmc">PMC11600088</ArticleId><ArticleId IdType="pubmed">39102652</ArticleId></ArticleIdList></Reference><Reference><Citation>White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I4-8. doi: 10.1161/01.CIR.0000078468.11849.66</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000078468.11849.66</ArticleId><ArticleId IdType="pubmed">12814979</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Hu S, Luo X, Bao X, Li J, Liu M, et al. Prevalence and prognostic significance of DNMT3A- and TET2- clonal haematopoiesis-driver mutations in patients presenting with ST-segment elevation myocardial infarction. EBioMedicine. 2022;78:103964. doi: 10.1016/j.ebiom.2022.103964</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.103964</ArticleId><ArticleId IdType="pmc">PMC8960977</ArticleId><ArticleId IdType="pubmed">35339897</ArticleId></ArticleIdList></Reference><Reference><Citation>Arends CM, Liman TG, Strzelecka PM, Kufner A, Lowe P, Huo S, et al. Associations of clonal hematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke. Blood. 2023;141:787&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">36441964</ArticleId></ArticleIdList></Reference><Reference><Citation>Todorovski A, Wang T-F, Carrier M, Xu Y. CHIP away at the marrow-clot connection: inflammation, clonal hematopoiesis, and thromboembolic disease. Blood Adv. 2025;9(2):343&#x2013;53. doi: 10.1182/bloodadvances.2024014430</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2024014430</ArticleId><ArticleId IdType="pmc">PMC11787476</ArticleId><ArticleId IdType="pubmed">39561373</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. doi: 10.1186/2046-4053-4-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2046-4053-4-1</ArticleId><ArticleId IdType="pmc">PMC4320440</ArticleId><ArticleId IdType="pubmed">25554246</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockliffe L. Including non&#x2010;English language articles in systematic reviews: a reflection on processes for identifying low&#x2010;cost sources of translation support. Res Synth Methods. 2022;13:2&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">34169665</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science. 2019;366(6465):eaan4673. doi: 10.1126/science.aan4673</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aan4673</ArticleId><ArticleId IdType="pmc">PMC8050831</ArticleId><ArticleId IdType="pubmed">31672865</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlasschaert C, Mack T, Heimlich JB, Niroula A, Uddin MM, Weinstock JS. A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic datasets. Blood. 2023. doi: blood.2022018825</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10273159</ArticleId><ArticleId IdType="pubmed">36652671</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuster JJ. Clonal hematopoiesis and coronary artery disease-a deep connection. JAMA Cardiol. 2024;9(3):242&#x2013;4. doi: 10.1001/jamacardio.2023.5106</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2023.5106</ArticleId><ArticleId IdType="pubmed">38198161</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao K, Shen X, Liu H, Lin Z, Li J, Chen S, et al. Somatic and germline variants and coronary heart disease in a Chinese population. JAMA Cardiol. 2024;9(3):233&#x2013;42. doi: 10.1001/jamacardio.2023.5095</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2023.5095</ArticleId><ArticleId IdType="pmc">PMC10782380</ArticleId><ArticleId IdType="pubmed">38198131</ArticleId></ArticleIdList></Reference><Reference><Citation>Khorana AA, McNamara MG, Kakkar AK, Streiff MB, Riess H, Vijapurkar U, et al. Assessing full benefit of rivaroxaban prophylaxis in high-risk ambulatory patients with cancer: thromboembolic events in the randomized CASSINI trial. TH Open. 2020;4(2):e107&#x2013;12. doi: 10.1055/s-0040-1712143</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1712143</ArticleId><ArticleId IdType="pmc">PMC7245534</ArticleId><ArticleId IdType="pubmed">32462111</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Committee Members, Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, et al. 2023. AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2023;82:833&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">37480922</ArticleId></ArticleIdList></Reference><Reference><Citation>Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;138(20):e618&#x2013;51. doi: 10.1161/CIR.0000000000000617</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000617</ArticleId><ArticleId IdType="pubmed">30571511</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJB, Culebras A, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(7):2064&#x2013;89. doi: 10.1161/STR.0b013e318296aeca</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STR.0b013e318296aeca</ArticleId><ArticleId IdType="pmc">PMC11078537</ArticleId><ArticleId IdType="pubmed">23652265</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden JA, van der Windt DA, Cartwright JL, C&#xf4;t&#xe9; P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158(4):280&#x2013;6. doi: 10.7326/0003-4819-158-4-201302190-00009</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-158-4-201302190-00009</ArticleId><ArticleId IdType="pubmed">23420236</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177&#x2013;88. doi: 10.1016/0197-2456(86)90046-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(86)90046-2</ArticleId><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;nemann HBJ
Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations. [Internet]. 2013. Available from: guidelinedevelopment.org/handbook</Citation></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Libby P, Sidlow R, Lin AE, Gupta D, Jones LW, Moslehi J, et al. Clonal hematopoiesis: crossroads of aging, cardiovascular disease, and cancer: JACC review topic of the week. J Am Coll Cardiol. 2019;74:567&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6681657</ArticleId><ArticleId IdType="pubmed">31345432</ArticleId></ArticleIdList></Reference><Reference><Citation>Svensson EC, Madar A, Campbell CD, He Y, Sultan M, Healey ML, et al. TET2-Driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial. JAMA Cardiology. 2022;7:521&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8988022</ArticleId><ArticleId IdType="pubmed">35385050</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>